FDA Approvals Reveal Antibacterial Rebound Masking Persistent Lack of Mechanistic Innovation
A pharmacology-centered analysis of FDA novel drug approvals from 2018 through mid-2026 shows that despite eighteen antibacterial authorizations, genuine structural ...

